DB:8XB

Stock Analysis Report

Executive Summary

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry, with a focus on oncology in Belgium and internationally.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Share Price & News

How has Biocartis Group's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-5.1%

DB:8XB

-2.0%

DE Medical Equipment

-1.6%

DE Market


1 Year Return

-17.8%

DB:8XB

3.4%

DE Medical Equipment

-10.5%

DE Market

8XB underperformed the Medical Equipment industry which returned 1.7% over the past year.

8XB underperformed the Market in Germany which returned -12% over the past year.


Share holder returns

8XBIndustryMarket
7 Day-5.1%-2.0%-1.6%
30 Day-8.9%-1.8%-5.4%
90 Day-14.4%-1.8%-6.0%
1 Year-17.8%-17.8%5.0%3.4%-7.7%-10.5%
3 Year40.7%40.7%111.2%105.6%9.4%-0.02%
5 Yearn/a264.0%246.0%25.5%8.1%

Price Volatility Vs. Market

How volatile is Biocartis Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Biocartis Group undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Biocartis Group's share price is below the future cash flow value, and at a moderate discount (> 20%).

Biocartis Group's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Biocartis Group is loss making, we can't compare its value to the DE Medical Equipment industry average.

Biocartis Group is loss making, we can't compare the value of its earnings to the Germany market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Biocartis Group, we can't assess if its growth is good value.


Price Based on Value of Assets

Biocartis Group is overvalued based on assets compared to the DE Medical Equipment industry average.


Next Steps

Future Growth

How is Biocartis Group expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

46.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Biocartis Group's revenue is expected to grow significantly at over 20% yearly.

Biocartis Group's earnings are expected to grow significantly at over 20% yearly.

Biocartis Group's revenue growth is expected to exceed the Germany market average.

Biocartis Group's earnings growth is expected to exceed the Germany market average.

Biocartis Group's earnings growth is expected to exceed the low risk savings rate of 0.2%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Biocartis Group will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Biocartis Group performed over the past 5 years?

-9.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Biocartis Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Biocartis Group's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Biocartis Group's 1-year growth to the DE Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Biocartis Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Biocartis Group has efficiently used its assets last year compared to the DE Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Biocartis Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Biocartis Group's financial position?


Financial Position Analysis

Biocartis Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Biocartis Group's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Biocartis Group's level of debt (20.4%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (37.9% vs 20.4% today).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 5.1x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Biocartis Group has sufficient cash runway for 1.3 years based on current free cash flow.

Biocartis Group has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -1.3% each year.


Next Steps

Dividend

What is Biocartis Group's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Biocartis Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Biocartis Group's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Biocartis Group has not reported any payouts.

Unable to verify if Biocartis Group's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Biocartis Group has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Biocartis Group's salary, the management and board of directors tenure and is there insider trading?

3.1yrs

Average management tenure


CEO

Herman Verrelst (45yo)

2.0yrs

Tenure

€510,000

Compensation

Mr. Herman Verrelst has been Chief Executive Officer of Biocartis Group NV since August 31, 2017. Mr. Verrelst serves as Director of European Operations at Detica Group Holdings (Ireland) Limited and of No ...


CEO Compensation Analysis

Herman's remuneration is lower than average for companies of similar size in Germany.

Herman's compensation has increased whilst company is loss making.


Management Age and Tenure

3.1yrs

Average Tenure

51yo

Average Age

The tenure for the Biocartis Group management team is about average.


Board Age and Tenure

1.9yrs

Average Tenure

55yo

Average Age

The average tenure for the Biocartis Group board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Herman Verrelst (45yo)

    CEO & Director

    • Tenure: 2.0yrs
    • Compensation: 510.00k
  • Susy Spruyt (51yo)

    Head of People & Organization

    • Tenure: 4.6yrs
  • Piet Houwen

    Chief Operating Officer

    • Tenure: 0.3yrs
  • Ewoud Welten (35yo)

    Chief Financial Officer

    • Tenure: 3.9yrs
  • Hilde Eylenbosch (55yo)

    Chief Commercial Officer

    • Tenure: 2.8yrs
  • Erwin Sablon (54yo)

    Head of R&D and Alliance Management

    • Tenure: 7.0yrs
  • Reginald Van Genechten (53yo)

    Head of Manufacturing & Supply Chain

    • Tenure: 3.4yrs
  • Geert Maertens

    Chairman of Scientific Advisory Board & Chief Scientific Officer

  • Renate Degrave

    Manager of Corporate Communications & Investor Relations

  • Benoit Devogelaere (38yo)

    Chief Technology Officer

    • Tenure: 1.7yrs

Board Members

  • Herman Verrelst (45yo)

    CEO & Director

    • Tenure: 1.9yrs
    • Compensation: 510.00k
  • Josep Tabernero

    Member of Scientific Advisory Board

  • Harry Glorikian (53yo)

    Non Executive Independent Director

    • Compensation: 27.11k
  • Leo Steenbergen (66yo)

    Non Executive Independent Director

    • Compensation: 25.69k
  • Ann-Christine Sundell (55yo)

    Non Executive Independent Director

    • Compensation: 28.69k
  • Luc Gijsens (65yo)

    Non-Executive Independent Director

    • Compensation: 27.92k
  • Roald Borré (46yo)

    Non-Executive Director

    • Tenure: 4.6yrs
    • Compensation: 36.24k
  • Eric Cutsem

    Member of Scientific Advisory Board

  • Christian Reinaudo (65yo)

    Chairman of the Board

    • Tenure: 1.3yrs
    • Compensation: 46.71k
  • Geert Maertens

    Chairman of Scientific Advisory Board & Chief Scientific Officer

Company Information

Biocartis Group NV's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biocartis Group NV
  • Ticker: 8XB
  • Exchange: DB
  • Founded: 2007
  • Industry: health care equipment
  • Sector: healthcare
  • Market Cap: €550.853m
  • Shares outstanding: 56.38m
  • Website: Click here

Number of Employees


Location

  • Biocartis Group NV
  • Generaal De Wittelaan 11 B3
  • Mechelen
  • Antwerp
  • 2800
  • Belgium

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BCARTENXTBR (Euronext Brussels)YesNew Ordinary SharesBEEURApr 2015
8XBDB (Deutsche Boerse AG)YesNew Ordinary SharesDEEURApr 2015
0R72LSE (London Stock Exchange)YesNew Ordinary SharesGBEURApr 2015
BCARTBBATS-CHIXE (BATS 'Chi-X Europe')YesNew Ordinary SharesGBEURApr 2015

Biography

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry, with a focus on onco ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/16 22:35
End of Day Share Price2019/08/16 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.